Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk

Despite intensive lowering of low-density lipoprotein cholesterol (LDL-C), many patients continue to experience atherosclerotic cardiovascular disease (ASCVD) events, with cholesterol-enriched remnant lipoproteins contributing to this residual risk. This review examines the evidence linking remnant lipoproteins to residual ASCVD risk and evaluates which treatment-induced changes in remnant exposure are likely to reduce it. Lipoprotein lipase (LPL), transported to the capillary lumen by GPIHBP1, converts triglyceride-rich lipoproteins into smaller remnants, the concentration of which is then determined by further remodeling and hepatic uptake. Once retained in the arterial wall, these remnants deliver cholesterol to macrophages and promote inflammation. In cohort studies, remnant cholesterol (RC) predicts cardiovascular events even among patients receiving lipid-lowering therapy, while Mendelian randomization and coding-variant analyses implicate LPL and its regulators in coronary artery disease. Trials evaluating triglyceride-lowering therapies, however, have yielded inconsistent results. In PROMINENT, pemafibrate lowered RC but elevated apolipoprotein B (apoB) and failed to reduce events. Agents targeting apolipoprotein C-III or angiopoietin-like protein 3 substantially lower triglycerides; their effects on RC, LDL-C, and apoB differ by agent and population; in the ESSENCE imaging study, olezarsen reduced both RC and apoB without significantly altering non-calcified plaque volume at 1 year. Building upon recent syntheses, we propose that these findings are best interpreted by separating four related dimensions of exposure: the cholesterol carried per remnant particle, the number of remnant particles, total apoB-containing particle exposure, and the rate of particle clearance. We apply this remnant-cholesterol-load framework to classify trial responses and to identify the measurements that future outcome trials should include. The framework is interpretive, and its dimensions are mathematically and kinetically related rather than independent; it has not been tested prospectively. At present, RC serves as a useful complement in assessing residual dyslipidemia; whether its reduction decreases events will be established only by outcome trials incorporating serial lipid and particle measurements.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fcvm.2026.1967973
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk

王小萍, Feng Liu, Yuting Huang, Luyao Lin
Frontiers in Cardiovascular Medicine
Lipoproteins and Cardiovascular Health
article

Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk

王小萍, Feng Liu, Yuting Huang, Luyao Lin
article en

Abstract

Despite intensive lowering of low-density lipoprotein cholesterol (LDL-C), many patients continue to experience atherosclerotic cardiovascular disease (ASCVD) events, with cholesterol-enriched remnant lipoproteins contributing to this residual risk. This review examines the evidence linking remnant lipoproteins to residual ASCVD risk and evaluates which treatment-induced changes in remnant exposure are likely to reduce it. Lipoprotein lipase (LPL), transported to the capillary lumen by GPIHBP1, converts triglyceride-rich lipoproteins into smaller remnants, the concentration of which is then determined by further remodeling and hepatic uptake. Once retained in the arterial wall, these remnants deliver cholesterol to macrophages and promote inflammation. In cohort studies, remnant cholesterol (RC) predicts cardiovascular events even among patients receiving lipid-lowering therapy, while Mendelian randomization and coding-variant analyses implicate LPL and its regulators in coronary artery disease. Trials evaluating triglyceride-lowering therapies, however, have yielded inconsistent results. In PROMINENT, pemafibrate lowered RC but elevated apolipoprotein B (apoB) and failed to reduce events. Agents targeting apolipoprotein C-III or angiopoietin-like protein 3 substantially lower triglycerides; their effects on RC, LDL-C, and apoB differ by agent and population; in the ESSENCE imaging study, olezarsen reduced both RC and apoB without significantly altering non-calcified plaque volume at 1 year. Building upon recent syntheses, we propose that these findings are best interpreted by separating four related dimensions of exposure: the cholesterol carried per remnant particle, the number of remnant particles, total apoB-containing particle exposure, and the rate of particle clearance. We apply this remnant-cholesterol-load framework to classify trial responses and to identify the measurements that future outcome trials should include. The framework is interpretive, and its dimensions are mathematically and kinetically related rather than independent; it has not been tested prospectively. At present, RC serves as a useful complement in assessing residual dyslipidemia; whether its reduction decreases events will be established only by outcome trials incorporating serial lipid and particle measurements.

Frontiers in Cardiovascular MedicineVol. 13
Gannan Medical University (CN), First Affiliated Hospital of Gannan Medical University (CN)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon